Silexion says SIL204 uses native serum lipids for cellular uptake, boosts KRAS knockdown in preclinical study

PUBT · 2d ago
Silexion says SIL204 uses native serum lipids for cellular uptake, boosts KRAS knockdown in preclinical study
  • Silexion Therapeutics reported preclinical data supporting systemic delivery of RNAi candidate SIL204 in KRAS-driven cancers.
  • Carrier-free assays showed dose-dependent mutant KRAS knockdown with physiological serum lipids; lipid depletion reduced silencing (P < 0.001).
  • Adding exogenous human LDL did not increase potency versus complete serum, indicating endogenous lipoprotein levels support cellular uptake.
  • Results underpin the Phase 2/3 program in locally advanced pancreatic cancer, supporting subcutaneous systemic dosing to target micro-metastatic disease.
  • Ongoing work includes in vivo pharmacokinetics and biodistribution to link lipoprotein association and LDL receptor engagement to anti-tumor activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280830PRIMZONEFULLFEED1001274927) on September 28, 2026, and is solely responsible for the information contained therein.